Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
desidustat
- Development stage
- Phase 4
- Lead developer
- Zydus Lifesciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Desidustat is an orally bioavailable small molecule drug developed for the treatment of anemia associated with chronic kidney disease (CKD), both in patients on dialysis and those not on dialysis. It acts as a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, stabilizing hypoxia-inducible factors and thereby stimulating endogenous erythropoietin production to promote erythropoiesis. Desidustat was discovered and developed by Zydus Life Sciences (formerly Zydus Cadila) and is marketed under the brand names Oxemia (by Zydus) and Rytstat (by Sun Pharma). The drug has received approval in India for anemia due to CKD, with ongoing clinical development for other indications such as chemotherapy-induced anemia, COVID-19-related anemia, sickle cell disease, inflammation-induced anemia, acute kidney injury, complement-mediated diseases, and stroke in CKD patients[1][2][4][7].
- Brand names
- OxemiaRytstat
- Other names
- desidustatZYAN1ZYAN-1ZYAN 1
02
Targets
EGLN1 (Prolyl hydroxylase domain-containing protein 2)PHD1 (Prolyl hydroxylase domain-containing protein 1)FIH-1 (Factor inhibiting hypoxia-inducible factor 1)PHD3 (Prolyl hydroxylase domain-containing protein 3)
Beyond the preview
Go deeper on desidustat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on desidustat.